Risk of acute promyelocytic leukemia in multiple sclerosis
Coding variants of DNA repair genes
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Background: Single nucleotide polymorphisms (SNPs) in double-strand break repair genes may alter DNA repair capacity and, in turn, confer predisposition to leukemia. We analyzed polymorphic variants of DNA repair and detoxification genes in patients with multiple sclerosis (MS) who developed secondary acute promyelocytic leukemia (sAPL), in most cases after treatment with mitoxantrone (MTZ).
Methods: Using MassARRAY high-throughput DNA analysis with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, we genotyped patients with sAPL (n = 20) developed after treatment of MS (18 out 20 treated with MTZ) for the presence of 210 SNPs of 22 genes mostly involved in DNA repair and drug detoxification. Patients with MS who did not develop sAPL including 41 treated with MTZ (n = 253 and 41, respectively) and healthy blood donors (n = 310) were also genotyped as controls.
Results: We observed risk allele frequency between MS and sAPL for BRCA2 (rs1801406): 6% and 26%, p = 0.007; XRCC5 (rs207906): 2.5% and 15%, p = 0.016; CYP3A4 (rs2740574): 4.5% and 25%, p = 0.0035. The association of homozygous variants of BRCA2 and XRCC5 yielded higher risk of sAPL (MS vs sAPL: 0.4% and 18%, p = 0.001). We also observed a significant association between a SNP in the promoter region (rs2740574) of CYP3A4, an enzyme involved in the metabolism of chemotherapeutic agents and development of sAPL.
Conclusions: Increased susceptibility to develop sAPL in patients with MS receiving MTZ may be linked to genetic variants in DNA repair and drug-metabolizing enzymes that result in impaired detoxification of chemotherapy or inefficient repair of drug-induced genetic damage.
Footnotes
-
- ATT
- Armitage trend test
- CI
- confidence interval
- FPRP
- false-positive report probability
- MS
- multiple sclerosis
- MTZ
- mitoxantrone
- NHEJ
- nonhomologous end-joining
- OR
- odds ratio
- sAML
- secondary acute myeloid leukemia
- sAPL
- secondary acute promyelocytic leukemia
- SNP
- single nucleotide polymorphism
-
Supplemental data at www.neurology.org
- Received September 8, 2010.
- Accepted November 23, 2010.
- Copyright © 2011 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Views & Reviews
Mitoxantrone-related acute leukemia in MSAn open or closed book?Andrew Chan, Francesco Lo-Coco et al.Neurology, April 15, 2013 -
Clinical Implications of Neuroscience Research
DNA damage responseSelected review and neurologic implicationsElizabeth A. Coon, Eduardo E. Benarroch et al.Neurology, January 19, 2018 -
Articles
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantroneV. Martinelli, E. Cocco, R. Capra et al.Neurology, November 09, 2011 -
Article
Novel susceptibility gene for nonfamilial hypokalemic periodic paralysisI-Wen Song, Chih-Chien Sung, Chien-Hsiun Chen et al.Neurology, March 02, 2016